What is the Level of IVF Technology in Georgia? Real Assessment and Comparison with Major Countries Worldwide

Direct Answer: Georgia’s IVF technology is at an upper-middle international level

According to publicly available assisted reproductive technology registry data and evaluation indicators from the International Society of Reproductive Medicine, Georgia’s overall IVF technology ranks in the upper-middle tier. Specific manifestations include:

• Proficiency in conventional in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), with clinical pregnancy rates close to the European average (approximately 40%‑45% per transfer cycle, not age-adjusted).
• Coverage of preimplantation genetic testing (PGT‑A/PGT‑M) exceeds 60%, with laboratories capable of conducting genetic screening.
• Frozen embryo thaw survival rate >95%, with vitrification technology widely adopted.
• However, advanced technologies such as time-lapse embryo imaging systems and artificial intelligence embryo scoring systems have not yet been widely implemented, available only in a few centers.

Doctor’s Perspective: A Mature “Cost-Effective Choice”

In interviews with practitioners who preferred to remain anonymous, several reproductive doctors stated that most medical teams in Georgia have trained in Ukraine, Russia, or Europe and follow standardized procedures. However, compared to the US and Japan, their advantage lies not in technological innovation but in the stable output of standard processes. Doctors recommend it as an option for the following groups:

• Patients with limited budgets who require PGT technology (costs about one-third of those in the US).
• Individuals with low antral follicle count (AFC <8) and low AMH (<1.2 ng/mL) who still have a chance to retrieve a few eggs—because Georgia allows the use of donor eggs with clear legal regulations.

Technology Comparison Across Countries: Georgia’s Position

As shown in the table, Georgia closely follows leading Eastern European countries in technical indicators, but overall live birth rates remain slightly lower than top centers in Western Europe and the US. The gap mainly stems from differences in embryo culture environments and hardware investment in genetics laboratories.

Easily Overlooked Detail: Laboratory Operational Stability

Most patients focus on the clinical experience of doctors, but there are differences in laboratory quality control among assisted reproduction centers in Georgia. Specific details include:

• Air purification systems: Some older centers have HVAC systems that cannot meet HEPA 13‑14 standards, potentially affecting embryo development (volatile organic compound concentration).
• Incubator sensor calibration: Temperature fluctuations in some small laboratories exceed ±0.5°C, while high-quality standards require ±0.1°C.
• Genetic testing outsourcing rate: When PGT samples must be sent to laboratories in Kyiv or Moscow, the result feedback cycle extends by 2‑3 weeks, and the risk of sample degradation during transport increases.

Therefore, even if the theoretical technical level is sufficient, the actual operational status should be evaluated by reviewing the center’s live birth rate reports (by age group) for the past three years.

Common Pitfall: Misinterpreting Success Rate Data

When searching for “Georgia IVF success rate,” patients often fall into the following traps:

1. Misleading mixed average data: Many websites claim a “60% success rate,” which actually refers to the clinical pregnancy rate for frozen embryo transfers in women under 35, not the live birth rate.
2. Selective reporting: Some centers only calculate “biochemical pregnancy after embryo transfer” rather than “live birth,” making such data less comparable.
3. Ignoring patient selection criteria: For older patients or those with diminished ovarian function, centers may recommend egg/sperm donation, thereby inflating their own “autologous egg success rate.”
4. Cycle volume differences: The technical stability gap between centers performing over 2,000 cycles annually and those performing fewer than 500 cycles is significant.

Actual Process: Standard Steps for IVF in Georgia

Required materials and procedures are as follows (using non-donor autologous eggs as an example):

• Pre-treatment tests: Complete hormone panel (FSH, LH, E2, etc.), AMH, vaginal ultrasound (antral follicle count), semen analysis, infectious disease screening, and chromosome karyotyping in your home country. Validity: blood tests/hormones 3 months; chromosome karyotype lifelong.
• Remote consultation: After submitting reports, a Georgian doctor will design an ovarian stimulation protocol.
• Visa and stay duration: Obtain an e-visa (30 days) or a multiple-entry visa. The first stimulation and egg retrieval require a stay of 12‑16 days; frozen embryo transfer requires an additional stay of 6‑8 days.
• Ovarian stimulation and egg retrieval: Medications (e.g., Gonal-f, Menopur) are used, and egg retrieval is performed under intravenous sedation in an outpatient setting.
• Embryo culture and PGT: Blastocyst culture for 5‑6 days, followed by biopsy and testing (results in approximately 8‑14 days).
• Transfer: Hormone replacement or natural cycle; pregnancy test 10‑12 days after transfer.

Cost Factors: Why Prices May Be Lower or Higher Than Expected

Actual total cost (autologous eggs + PGT + one transfer) is approximately 8,000‑15,000 USD. Additional cycles or use of donor eggs will increase costs. Also factor in round-trip airfare, accommodation, translation, and living expenses.

Practitioner Observation: Hidden Gaps in Technological Catch-Up

Coordinators who have worked with multiple Eastern European centers point out that Georgia still has room for improvement in the following areas:

• Embryologist training system: There is currently no national embryology certification exam, leading to varying skill levels.
• Transparency of quality control: Few centers proactively publish annual SART-style cycle reports (live birth rates for ≤30/31‑35/36‑40 age groups).
• Management of recurrent miscarriage: For patients with recurrent implantation failure (RIF), some centers lack advanced options such as endometrial receptivity analysis (ERA) or chronic endometritis screening.

These gaps do not hinder basic cycle treatment, but for complex cases (≥40 years old, repeated failure, genetic disease carriers), Georgia may not be the optimal choice.

Risk Reminder

Before choosing IVF in Georgia, be sure to consider the following risks:

1. Legal change risk: Georgia’s laws on assisted reproduction (especially surrogacy) are under periodic revision, with some clauses regarding parental rights for foreign parents being ambiguous. Particularly regarding the nationality of surrogate-born children, consulting a local international family lawyer is recommended.
2. Difficulty in cross-border medical error accountability: In the event of major laboratory errors (embryo loss, mix-up), the local medical dispute resolution process is slow, and language barriers may increase the cost of seeking recourse.
3. Communication efficiency: Not all doctors are fluent in English, and translators’ varying understanding of reproductive terminology may lead to medication misunderstandings.

Recommendations for patients planning to travel:

• Request the center to provide English versions of laboratory quality indicators (fertilization rate, blastocyst formation rate, freeze-thaw survival rate).
• Prioritize centers performing >800 cycles annually and those that can display live birth rate tables (stratified by age).
• Keep all original medical records (including stimulation protocols, embryo photos, genetic reports).